Financial News

Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Jazz Pharmaceuticals plc - Ordinary Shares (NQ: JAZZ )

133.96 -2.86 (-2.09%)
Streaming Delayed Price Updated: 4:00 PM EST, Feb 14, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 845,113
Open 137.14
Bid (Size) 125.00 (1)
Ask (Size) 137.90 (5)
Prev. Close 136.82
Today's Range 133.25 - 137.92
52wk Range 99.06 - 138.27
Shares Outstanding 62,311,104
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
This AstraZeneca Analyst Turns Bullish; Here Are Top 5 Upgrades For Thursday
Via Benzinga
Deep Dive Into Jazz Pharmaceuticals Stock: Analyst Perspectives (9 Ratings)
Via Benzinga

Performance

YTD
+8.24%
+8.24%
1 Month
+9.25%
+9.25%
3 Month
+13.92%
+13.92%
6 Month
+17.26%
+17.26%
1 Year
+5.66%
+5.66%

More News

Read More
Investors should take notice of NASDAQ:JAZZ—it offers a great deal for the fundamentals it presents.
Via Chartmill
NASDAQ:JAZZ, an undervalued stock with good fundamentals.
Via Chartmill
NASDAQ:JAZZ is an undervalued gem with solid fundamentals.
Via Chartmill
CBD Drug For Tuberous Sclerosis: Caregivers Continue Epidiolex Treatment Citing Seizure Reduction And Cognitive Improvements
Via Benzinga
NASDAQ:JAZZ, an undervalued stock with good fundamentals.
Via Chartmill
In-Depth Examination Of 12 Analyst Recommendations For Jazz Pharmaceuticals
Via Benzinga
Axsome Therapeutics' AXS-12 Data For Sleeping Disorder Boosts Confidence In Approval And Market Potential, Analyst Says
Via Benzinga
NASDAQ:JAZZ is a prime example of a stock that offers more than what meets the eye in terms of fundamentals.
Via Chartmill
FDA Greenlights Jazz Pharma's Cancer Drug, A Milestone For Zymework
Via Benzinga
Exposures Product Safety
UK Parents Want National Health Service To Allow Cannabis For Children With Epilepsy
Via Benzinga
Topics Cannabis
Exposures Cannabis
Jazz Pharmaceuticals Reports Strong Q3: Will Debt Weigh On Its Future Growth?
Via Benzinga
Assessing Jazz Pharmaceuticals: Insights From 12 Financial Analysts
Via Benzinga
Despite its impressive fundamentals, NASDAQ:JAZZ remains undervalued.
Via Chartmill
A Closer Look at 12 Analyst Recommendations For Jazz Pharmaceuticals
Via Benzinga
A Closer Look at 12 Analyst Recommendations For Jazz Pharmaceuticals
Via Benzinga
Billionaire Seth Klarman Sold 64% of Baupost's Stake in Alphabet and Is Piling Into This Historically Cheap and Under-the-Radar Drugmaker
Via The Motley Fool
Jazz Pharmaceuticals' Zepzelca/Tecentriq Combo Regimen Can Potentially Delay Disease Progression, Extend Survival In Aggressive Form Of Lung Cancer
Via Benzinga
NASDAQ:JAZZ is a prime example of a stock that offers more than what meets the eye in terms of fundamentals.
Via Chartmill
FDA-Approved Cannabis-Based Drug Shows Promising Results As A Treatment For War Veterans: Study Finds Improvement In Cognitive, Mood, Pain-Related Symptoms
Via Benzinga
When you look at NASDAQ:JAZZ, it's hard to ignore the strong fundamentals, especially considering its likely undervaluation.
Via Chartmill
Jazz And Hikma Accused Of Delaying Sleep Disorder Generic Drug To Maintain High Prices
Via Benzinga
'From Five Minutes Of Agony, It's Now Just Seconds,' Says Brazilian Mother Celebrating Free Access To Her Child's Life-Saving CBD Medicine
Via Benzinga
The Only FDA-Approved CBD Treatment For Severe Epilepsy Completes Key Phase 3 Trial In Japan Despite Missed Primary Goal
Via Benzinga
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.

Use the myMotherLode.com Keyword Search to go straight to a specific page

Popular Pages

  • Local News
  • US News
  • Weather
  • State News
  • Events
  • Traffic
  • Sports
  • Dining Guide
  • Real Estate
  • Classifieds
  • Financial News
  • Fire Info
Terms of Service Privacy Policy
© Copyright 2000-2019 Clarke Broadcasting Corporation. All rights reserved.
Feedback